Precision for Value Expands Health Economics and Outcomes Research Team

February 19, 2015, New York – Precision for Value (, a Precision for Medicine Company, which provides health economics, analytics, and marketing communications services to life sciences clients, today announced the expansion of its Health Economics and Outcomes Research (HEOR) Team to meet growing customer demand. Dr. Bob Nordyke was appointed as senior vice president, Health Economics and Evidence Strategy, Phil Cyr was named vice president, health economics and, Ellynne Dec was named senior principal, health economics.

“The fusing of health economics, market analytics, and strategic communication under the brand of Precision for Value is pointed squarely at where the market is headed,” said Dan Renick, president of Precision for Value. “Commercial clients are increasingly realizing that demonstrating and communicating value will be the challenge that separates winners from losers in the marketplace and that they need solutions that are faster, flexible, and innovative. We’re thrilled to add world-class HEOR experts like Bob, Phil, and Ellynne to our growing team, and confident their capabilities will further help our clients achieve commercial excellence through value demonstration that addresses unmet patient needs in the era of precision medicine.”

Dr. Bob Nordyke, PhD is responsible for delivering scientifically rigorous and commercially relevant services to global biopharma clients. Dr. Nordyke brings over 25 years of experience in health economics, outcomes research, and health policy experience. Dr. Nordyke has identified, built, and supported the economic value of biopharma products from the earliest stages of development to loss of exclusivity. Before joining Precision for Value, Dr. Nordyke established the health economics practice at PriceSpective and went on to lead the health economics practice following ICON Plc’s acquisition of PriceSpective and Oxford Outcomes. Prior to ICON, Dr. Nordyke was part of Amgen’s Global Health Economics team, where he served as the therapeutic area head for inflammation, the global payer lead and global health economics lead in oncology, and was the founding program lead for an EMR-based registry in oncology. Earlier he was the Director of Outcomes Research at Cerner LifeSciences, and a research fellow at the RAND Corporation.

Dr. Nordyke is an adjunct professor at the UCLA School of Public Health, formerly a lecturer at USC, and has authored or coauthored dozens of papers in leading journals such as the Journal of Managed Care Pharmacy, Value in Health and Social Science and Medicine. He received his Doctor of Philosophy from the RAND Graduate School and a Master’s from the University of Texas-Austin.

Phil Cyr is focused on developing and executing academically and commercially relevant health economic and outcome research studies and services for biopharma, medical device, and diagnostics clients. Mr. Cyr brings over 20 years of experience in health economics, outcomes research, health policy, and payer experience to Precision for Value. He offers practical knowledge of the global payer technology review process, having worked in technology assessment in the U.S. and Europe. Before joining Precision for Value, Mr. Cyr was Senior Director of Health Economics at PriceSpective and Icon Plc. where he drove the cross-function integration of the health economic practice across ICON’s Pricing and Market Access, Payer Engagement, and Peri-Approval practices. Prior to joining ICON, Mr. Cyr initiated and developed health economic practices for two healthcare consulting organizations, Navigant Consulting and Boston Healthcare Associates. Earlier in his career he held research and strategy positions at the Massachusetts General Hospital, Blue Cross and Blue Shield of Massachusetts, HCIA, Inc., and New England Medical Center.

Mr. Cyr has been an Adjunct Professor at the George Mason University School of Management and has coauthored numerous papers in leading journals such as American Journal of Health-System Pharmacy, Clinical Therapeutics, Cancer, and European Molecular Biology Organization (EMBO) Reports. He is also a peer reviewer for the American Journal of Managed Care. He received a Masters of Public Health, with concentrations in epidemiology and biostatistics, from the Boston University School of Public Health, and a Bachelor of Arts degree in biology and history from Kenyon College.

Ellynne Dec is a decision analyst and an actuary, and contributes over two decades of strategic economic advisory experience to Precision for Value. She contributes significant analytic and big data capabilities and international drug development experience to the team. Before joining Precision for Value, Ms. Dec was a healthcare actuary at Milliman, developing innovative cost impact and population health analyses using both real-world and clinical data sets. Prior to her work at Milliman, Ms. Dec was Director of Analytics and Operations at Novartis, and provided decision analytic support in a broad range of therapeutic areas and clinical operations. She also brings to Precision for Value over 10 years of experience in the United Kingdom, where she worked with the NHS, Department of Health, and other clients, building forecasting and valuation tools and developing cost impact analyses and “Green Book” appraisals.

Ms. Dec is an Adjunct Professor at both the Columbia University Business School and the Mailman School of Public Health. She has coauthored papers on cost and risk analysis, in publications including, most recently, American Health and Drug Benefits. She was a PhD candidate at Stanford University in Engineering Economic Systems, where she was a research assistant for Professor Ron Howard in the Decisions and Ethics Center. She is an Associate of the Society of Actuaries, and received a Bachelor of Arts degree in philosophy and logic at Smith College.

About Precision for Value

Precision for Value supports commercial excellence for global pharmaceutical and life sciences clients through the proficient demonstration of product value and outcomes. With locations in New York City, New Jersey, Chicago, Boston, Connecticut, and Indianapolis, Precision for Value’s teams provide clients with services grounded in decades of industry knowledge, demonstrated analytics proficiency, and marketing and communications prowess— making Precision for Value the preferred strategic partner in the industry. For more information visit

About Precision for Medicine

Precision for Medicine is a specialized company providing services and infrastructure to support life sciences companies as they develop new products in the age of precision medicine. Precision brings expertise, technology, and project execution to support innovative, patient-centric solutions from discovery through commercialization. The company is headquartered in Bethesda, MD. Visit for more information.

# # #

Media Contact

Randy Zane

Precision for Medicine Media Relations

212-686-2650, ext. 3027

Randy Zane

Senior Director, Marketing Communications

Precision for Value

9 East 37th Street | New York, NY 10016

212 686 2650 office

212 686 2693 fax

A Precision for Medicine Company